Open Nav

Salarius Pharmaceuticals


  • Date:Thursday, October 18
  • Time:3:00 PM - 3:15 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Salarius is leveraging $21M in non-dilutive funds and a management team with over 100 years experience in pharmaceuticals to bring a novel cancer treatment to people who need it the most. Salarius is first targeting a rare pediatric bone cancer so aggressive that patients have less than a 10% chance to survive for five years or more. Next, Salarius is targeting subtypes of breast, ovarian, and prostate cancer representing the #1 causes of cancer-related mortality in men & women. Salarius will be starting Phase 1 trials this month and eyeing a 2020 exit.
  • Company
  • Company HQ City:Houston
  • Company HQ Country:United States
  • Company HQ State:Texas                            
  • CEO/Top Company Official:David Arthur
  • Year Founded:2011
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Seclidemstat
  • Development Phase of Primary Product:Phase I
  • Additional Information/Comments:Raising $7M Series A round which, with the $21M in non-dilutive funding, will fund 5 Phase 1 clinical trials.
  • Previous and Current Investors:GPG Ventures, Keiretsu Capital, South Coast ANgels, Houston Angel Network, Tech Coast Angels,+ more
  • Size of Last Investment Round:2.4--Series 1
  • Total Amount Raised to Date, In All Rounds:19.5M
  • Address 1: 2450 Holcombe Boulevard
  • Address 2:Suite J-608
Daniela Santiesteban
Salarius Pharmaceuticals